DK1165112T3 - Modulatorer af polysaccharider og anvendelser deraf - Google Patents

Modulatorer af polysaccharider og anvendelser deraf

Info

Publication number: DK1165112T3
Authority: DK; Denmark
Prior art keywords: glycosaminoglycan; peptides; sulfate; chitosan; mediated processes
Prior art date: 1999-03-26

Application number

DK00919594T

Other languages

English (en)

Inventor

Akira Takashima

Mansour Mohamadzadeh

Mark E Mummert

Original Assignee

Univ Texas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-26

Filing date

2000-03-22

Publication date

2006-10-09

2000-03-22 Application filed by Univ Texas filed Critical Univ Texas

2006-10-09 Application granted granted Critical

2006-10-09 Publication of DK1165112T3 publication Critical patent/DK1165112T3/da

Links

150000004676 glycans Chemical class 0.000 title 1
229920001282 polysaccharide Polymers 0.000 title 1
239000005017 polysaccharide Substances 0.000 title 1
229920002683 Glycosaminoglycan Polymers 0.000 abstract 5
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
229920001661 Chitosan Polymers 0.000 abstract 2
208000015181 infectious disease Diseases 0.000 abstract 2
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 abstract 1
229920002101 Chitin Polymers 0.000 abstract 1
229920001287 Chondroitin sulfate Polymers 0.000 abstract 1
229920000045 Dermatan sulfate Polymers 0.000 abstract 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
229920000288 Keratan sulfate Polymers 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000008827 biological function Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 abstract 1
229940059329 chondroitin sulfate Drugs 0.000 abstract 1
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 abstract 1
229940051593 dermatan sulfate Drugs 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
239000003623 enhancer Substances 0.000 abstract 1
230000006870 function Effects 0.000 abstract 1
229920000669 heparin Polymers 0.000 abstract 1
229960002897 heparin Drugs 0.000 abstract 1
229920002674 hyaluronan Polymers 0.000 abstract 1
229960003160 hyaluronic acid Drugs 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000003068 molecular probe Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicinal Preparation (AREA)
Polyesters Or Polycarbonates (AREA)

DK00919594T 1999-03-26 2000-03-22 Modulatorer af polysaccharider og anvendelser deraf DK1165112T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12647599P	1999-03-26	1999-03-26

Publications (1)

Publication Number	Publication Date
DK1165112T3 true DK1165112T3 (da)	2006-10-09

Family

ID=22425031

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00919594T DK1165112T3 (da)	1999-03-26	2000-03-22	Modulatorer af polysaccharider og anvendelser deraf

Country Status (13)

Country	Link
US (2)	US6653285B1 (da)
EP (1)	EP1165112B1 (da)
JP (1)	JP2002540161A (da)
AT (1)	ATE328603T1 (da)
AU (1)	AU774650B2 (da)
CA (1)	CA2366604A1 (da)
CY (1)	CY1105531T1 (da)
DE (1)	DE60028558T2 (da)
DK (1)	DK1165112T3 (da)
ES (1)	ES2265928T3 (da)
MX (1)	MXPA01009690A (da)
PT (1)	PT1165112E (da)
WO (1)	WO2000057896A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1430302A4 (en) *	2001-03-21	2007-08-22	Univ Texas	Glycosaminoglycan INHIBITORS
US20040259783A1 (en) *	2001-11-09	2004-12-23	Tony Cruz	Pharmaceutical compositions of marine sponge microciona prolifera
ITPD20020003A1 (it)	2002-01-11	2003-07-11	Fidia Advanced Biopolymers Srl	Biomateriali a base di acido ialuronico come terapia anti-angiogenicanella cura dei tumori.
WO2005016364A1 (en) *	2003-08-14	2005-02-24	Guthy-Renker Corporation	Skin care composition including hexapeptide complexes and methods of their manufacture
US20060198800A1 (en) *	2003-08-14	2006-09-07	Natalie Dilallo	Skin care compositions including hexapeptide complexes and methods of their manufacture
AU2009270405B2 (en)	2008-06-30	2014-06-05	Esbatech, An Alcon Biomedical Research Unit Llc	Functionalized polypeptides
JP2011526925A (ja) *	2008-07-01	2011-10-20	ザカロンファーマシューティカルズ，インク．	ヘパラン硫酸阻害剤
US8232073B2 (en)	2009-01-02	2012-07-31	Zacharon Pharmaceuticals, Inc.	Quantification of non-reducing end glycan residual compounds
US8592140B2 (en)	2009-01-02	2013-11-26	Biomarin Pharmaceutical Inc.	Detection of oligosaccharides
US9029530B2 (en) *	2009-01-02	2015-05-12	Biomarin Pharmaceutical Inc.	Detection of oligosaccharides
US8809009B2 (en)	2009-01-02	2014-08-19	Biomarin Pharmaceutical Inc.	Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
US20130071408A1 (en) *	2010-02-01	2013-03-21	Atul J. Butte	Methods for Diagnosis and Treatment of Non-Insulin Dependent Diabetes Mellitus
PL3249662T3 (pl) *	2016-05-27	2020-11-16	Hanning Elektro-Werke Gmbh & Co. Kg	Silnik elektryczny do napędu pompy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9207949D0 (en) *	1992-04-09	1992-05-27	Univ Manitoba	Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
US5981478A (en) *	1993-11-24	1999-11-09	La Jolla Cancer Research Foundation	Integrin-binding peptides
CA2237051A1 (en) *	1997-12-19	1999-06-19	Eva A. Turley	Enhanced affinity hyaluronan binding peptides
CA2448483A1 (en) *	2000-10-05	2002-04-11	Transition Therapeutics Inc.	Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans

2000
- 2000-03-22 EP EP00919594A patent/EP1165112B1/en not_active Expired - Lifetime
- 2000-03-22 MX MXPA01009690A patent/MXPA01009690A/es active IP Right Grant
- 2000-03-22 JP JP2000607646A patent/JP2002540161A/ja active Pending
- 2000-03-22 WO PCT/US2000/007813 patent/WO2000057896A1/en not_active Ceased
- 2000-03-22 AT AT00919594T patent/ATE328603T1/de not_active IP Right Cessation
- 2000-03-22 CA CA002366604A patent/CA2366604A1/en not_active Abandoned
- 2000-03-22 US US09/532,709 patent/US6653285B1/en not_active Expired - Fee Related
- 2000-03-22 DE DE60028558T patent/DE60028558T2/de not_active Expired - Fee Related
- 2000-03-22 PT PT00919594T patent/PT1165112E/pt unknown
- 2000-03-22 DK DK00919594T patent/DK1165112T3/da active
- 2000-03-22 AU AU40255/00A patent/AU774650B2/en not_active Ceased
- 2000-03-22 ES ES00919594T patent/ES2265928T3/es not_active Expired - Lifetime
2003
- 2003-10-06 US US10/680,670 patent/US6923965B2/en not_active Expired - Fee Related
2006
- 2006-08-23 CY CY20061101185T patent/CY1105531T1/el unknown

Also Published As

Publication number	Publication date
DE60028558T2 (de)	2007-05-16
WO2000057896A1 (en)	2000-10-05
EP1165112A4 (en)	2002-09-25
JP2002540161A (ja)	2002-11-26
ES2265928T3 (es)	2007-03-01
MXPA01009690A (es)	2003-06-24
EP1165112B1 (en)	2006-06-07
CY1105531T1 (el)	2010-07-28
DE60028558D1 (de)	2006-07-20
CA2366604A1 (en)	2000-10-05
US6653285B1 (en)	2003-11-25
US6923965B2 (en)	2005-08-02
PT1165112E (pt)	2006-10-31
US20040138105A1 (en)	2004-07-15
AU4025500A (en)	2000-10-16
AU774650B2 (en)	2004-07-01
ATE328603T1 (de)	2006-06-15
EP1165112A1 (en)	2002-01-02

Similar Documents

Publication	Publication Date	Title
DK1165112T3 (da)	2006-10-09	Modulatorer af polysaccharider og anvendelser deraf
ES2619181T3 (es)	2017-06-23	Hidrogel quirúrgico
NZ333925A (en)	2000-07-28	Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
JP2006502129A5 (da)	2006-06-15
DE69533370D1 (de)	2004-09-16	Heparinähnliche sulfatierte Polysaccharide
DE69928952D1 (de)	2006-01-19	Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe
EP1689348A4 (en)	2008-11-26	OLIGOSACCHARIDE COMPOSITIONS AND ITS USE IN THE TREATMENT OF INFECTIONS
WO2007070547A3 (en)	2007-08-16	Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
BRPI0418384A (pt)	2007-06-26	composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
EP1532241A4 (en)	2005-12-14	Rationally Constructed Lyases Derived from Chondroitinase B.
BRPI0409890A (pt)	2006-05-23	processo para a produção de um gel de polissacarìdeo reticulado, gel de polissacarìdeo reticulado substancialmente resistente à degradação de hialuronidase, composição farmacêutica, método para o tratamento ou a prevenção de um distúrbio ou uma condição selecionada do grupo que consiste em aumento de tecido, artrite, aderências de tecidos, capacidade imunogênica, doenças da mucosa, condições dermatológicas, condições oftalmológicas, condições hormonais, condições de lubrificação das juntas e condições cosméticas, em um indivìduo com necessidade do mesmo e uso de um gel
BR9608041A (pt)	1999-01-26	Oligossacarídeo sulfatado processo para o tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório de um paciente humano ou outro paciente animal de sangue quente uso de um oligossacarídeo e composição farmacêutica ou veterinária para tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório
EA200000911A1 (ru)	2001-04-23	Новые кристаллические формы антивирусного соединения бензимидазола
PT1303632E (pt)	2005-02-28	Oligossacarideos de galactomanano e processo para a sua preparacao bem como sua utilizacao
BR0314613A (pt)	2005-07-26	Conjuntos de processamento de fluidos e organizadores para os mesmos
BR0012087A (pt)	2002-04-02	Composições compreendendo copolìmeros em bloco hidrogenados e aplicações de uso final dos mesmos
BR9508323A (pt)	1998-01-06	Uso de quitosan e um polissacarídeo imobilizado no mesmo escolhido dentre heparina sulfato de herpan e sulfato de extran e processo para impedir ou reduzir substancialmente a adesão indesejável de tecidos com relação à cicatrização de feridas
BRPI0516568A (pt)	2008-09-09	biomateriais consistindo em ácido hialurÈnico sulfatado e gelana, bem como composição farmacêutica e uso dos mesmos
BR9808008A (pt)	2000-03-08	Processo para o tratamento anticoagulante e/ou antitrombótico de um ser humano ou outro paciente animal de sangue quente, usos de um oligossacarìdeo sulfatado e na fabricação de um medicamento, e, composição farmacêutica ou veterinária para tratamento anticoagulante e/ou antitrombótico.
DE69316758D1 (de)	1998-03-05	Selbstvernetztes gellangummi
BRPI0408889A (pt)	2006-04-11	uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
BR0014372A (pt)	2002-06-25	Derivados de 5-hidroxissapogenina com atividade antidemência
GB0322448D0 (en)	2003-10-29	Using lamellar bodies to modify linear biological macro molecules
BR9911785A (pt)	2001-04-03	Combinações de farnesil transferase de proteìna e inibidores de redutase de hmg coa e seu uso para tratar câncer
DK1037642T3 (da)	2009-07-06	Modificerede polysaccharider med ændret biologisk genkendelse